PHOENIX Trial Testing Genes to Guide Medicine Choices in Hospital and Specialist Care

What this Trial Is About

Researchers are studying how genetic differences affect peoples responses to medicines, which can cause benefits, no effects, or side-effects. This study, called PHOENIX, aims to see if genetic testing before prescribing new medicines can reduce harmful reactions and treatment failures in adult patients admitted to hospital or attending outpatient clinics. It also assesses the cost impact of this genetic-guided care. Participants include adults from various medical specialties who receive medicines with known genetic implications. Participants will be randomly assigned to one of two groups. One group will have their genetic test results analyzed immediately to guide medication decisions, while the other group will have testing done after three months as standard care. All participants provide a cheek swab for DNA testing. The results help doctors decide if any medication changes are needed. Both groups will be monitored for medication side-effects, changes, and quality of life over three months. During the study, participants will complete questionnaires monthly on quality of life, medication adherence, and side-effects. Blood tests may be done around four weeks based on the medication used. Researchers will also collect data on hospital admissions, new prescriptions, and deaths from health records. The main outcome measured is the combination of adverse drug reactions and treatment failures within three months. The study involves follow-up for at least 12 weeks, with safety and health economic evaluations included.

PRE-EMPTIVE PHARMACOGENOMICS IN ACUTE CARE SETTINGS WITH HEALTH ECONOMIC EVALUATIONS (PHOENIX TRIAL)